Loading...

Capricor Therapeutics

Nasdaq:CAPR
Snowflake Description

Reasonable growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CAPR
Nasdaq
$17M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Capricor Therapeutics has significant price volatility in the past 3 months.
CAPR Share Price and Events
7 Day Returns
-8.6%
NasdaqCM:CAPR
-5.5%
US Biotechs
-0.1%
US Market
1 Year Returns
-63.2%
NasdaqCM:CAPR
-2.6%
US Biotechs
7.6%
US Market
CAPR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Capricor Therapeutics (CAPR) -8.6% -10.2% -9.8% -63.2% -87% -90.1%
US Biotechs -5.5% -3% -3.2% -2.6% -1.9% 16.6%
US Market -0.1% 3.7% 10.2% 7.6% 38.1% 46.4%
1 Year Return vs Industry and Market
  • CAPR underperformed the Biotechs industry which returned -2.6% over the past year.
  • CAPR underperformed the Market in United States of America which returned 7.6% over the past year.
Price Volatility
CAPR
Industry
5yr Volatility vs Market

Value

 Is Capricor Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Capricor Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $0.4937.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Capricor Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Capricor Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CAPR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.52
NasdaqCM:CAPR Share Price ** NasdaqCM (2019-04-23) in USD $0.49
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.73x
United States of America Market PE Ratio Median Figure of 3,080 Publicly-Listed Companies 18.03x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Capricor Therapeutics.

NasdaqCM:CAPR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CAPR Share Price ÷ EPS (both in USD)

= 0.49 ÷ -0.52

-0.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Capricor Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Capricor Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Capricor Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:CAPR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
14.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.76x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.55x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Capricor Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Capricor Therapeutics's assets?
Raw Data
NasdaqCM:CAPR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.15
NasdaqCM:CAPR Share Price * NasdaqCM (2019-04-23) in USD $0.49
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.27x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqCM:CAPR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CAPR Share Price ÷ Book Value per Share (both in USD)

= 0.49 ÷ 0.15

3.36x

* Primary Listing of Capricor Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Capricor Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Capricor Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Capricor Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Capricor Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Capricor Therapeutics expected to grow at an attractive rate?
  • Capricor Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Capricor Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Capricor Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CAPR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CAPR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 14.1%
NasdaqCM:CAPR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 65%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CAPR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CAPR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 51 15 1
2022-12-31 0 -25 1
2021-12-31 0 -20 1
2020-12-31 1 -21 1
2019-12-31 1 -8 1
NasdaqCM:CAPR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -14 -15
2018-09-30 1 -13 0
2018-06-30 2 -13 2
2018-03-31 2 -13 2
2017-12-31 3 -14 2
2017-09-30 3 -15 -14
2017-06-30 4 -14 -17
2017-03-31 4 -15 -18
2016-12-31 4 -14 -19
2016-09-30 4 -15 -18
2016-06-30 5 -16 -15
2016-03-31 5 -13 -14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Capricor Therapeutics's earnings are expected to grow by 14.1% yearly, however this is not considered high growth (20% yearly).
  • Capricor Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CAPR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Capricor Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CAPR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.19 0.19 0.19 1.00
2022-12-31 -0.33 -0.33 -0.33 1.00
2021-12-31 -0.28 -0.28 -0.28 1.00
2020-12-31 -0.41 -0.29 -0.52 2.00
2019-12-31 -0.19 -0.19 -0.19 1.00
NasdaqCM:CAPR Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.52
2018-09-30 0.01
2018-06-30 0.07
2018-03-31 0.10
2017-12-31 0.10
2017-09-30 -0.65
2017-06-30 -0.82
2017-03-31 -0.92
2016-12-31 -1.01
2016-09-30 -1.02
2016-06-30 -0.91
2016-03-31 -0.84

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Capricor Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Capricor Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Capricor Therapeutics has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Capricor Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Capricor Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Capricor Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Capricor Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Capricor Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Capricor Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Capricor Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CAPR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.67 -15.19 4.93
2018-09-30 1.50 0.37 5.06
2018-06-30 1.59 1.78 4.89
2018-03-31 2.19 2.43 4.96
2017-12-31 2.67 2.43 4.76
2017-09-30 3.10 -14.39 4.68
2017-06-30 3.53 -16.99 4.85
2017-03-31 3.66 -18.21 5.04
2016-12-31 4.00 -18.81 4.93
2016-09-30 4.22 -17.63 4.86
2016-06-30 4.78 -15.21 4.57
2016-03-31 4.94 -13.65 4.06
2015-12-31 5.52 -12.86 4.37
2015-09-30 5.80 -11.44 3.98
2015-06-30 5.78 -10.07 3.83
2015-03-31 5.53 -8.48 3.56
2014-12-31 4.79 -6.22 3.02
2014-09-30 3.38 -8.59 3.01
2014-06-30 2.16 -8.59 2.75
2014-03-31 1.31 -8.69 2.59
2013-12-31 0.50 -8.89 2.21
2013-09-30 1.08 -4.61 1.81
2013-06-30 1.50 -3.66 1.56
2013-03-31 1.72 -2.76 1.45
2012-12-31 1.90 -2.07 1.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Capricor Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Capricor Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Capricor Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Capricor Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Capricor Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Capricor Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Capricor Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Capricor Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Capricor Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Capricor Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Capricor Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Capricor Therapeutics Company Filings, last reported 3 months ago.

NasdaqCM:CAPR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4.62 0.00 7.26
2018-09-30 6.98 0.00 10.37
2018-06-30 9.63 0.00 12.33
2018-03-31 10.53 0.00 13.16
2017-12-31 11.23 0.00 14.12
2017-09-30 -4.27 14.16 13.89
2017-06-30 -6.59 14.16 12.26
2017-03-31 -7.19 13.91 11.74
2016-12-31 -4.00 13.91 16.19
2016-09-30 0.05 13.91 20.52
2016-06-30 -5.12 12.16 11.35
2016-03-31 -1.08 10.16 14.26
2015-12-31 -1.03 9.16 13.57
2015-09-30 1.93 9.16 17.22
2015-06-30 4.56 9.16 20.53
2015-03-31 7.32 9.16 22.42
2014-12-31 -6.25 9.16 8.03
2014-09-30 -4.47 9.16 10.13
2014-06-30 -3.08 8.64 11.91
2014-03-31 -1.66 3.96 13.31
2013-12-31 -0.53 3.96 2.06
2013-09-30 0.51 3.96 1.90
2013-06-30 1.95 0.89 3.34
2013-03-31 4.89 0.00 4.36
2012-12-31 4.89 0.00 4.36
  • Capricor Therapeutics has no debt.
  • Capricor Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Capricor Therapeutics has less than a year of cash runway based on current free cash flow.
  • Capricor Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.3% each year.
X
Financial health checks
We assess Capricor Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Capricor Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Capricor Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Capricor Therapeutics dividends.
If you bought $2,000 of Capricor Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Capricor Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Capricor Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CAPR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CAPR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Capricor Therapeutics has not reported any payouts.
  • Unable to verify if Capricor Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Capricor Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Capricor Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Capricor Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Capricor Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Capricor Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Capricor Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Linda Marbán
COMPENSATION $602,109
AGE 55
TENURE AS CEO 9.3 years
CEO Bio

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has been the key negotiator in the licensing agreements, which have provided to Capricor its intellectual property estate, as well as spearHeading Capricor’s fundraising efforts. She served as the Acting Chief Executive Officer of Capricor Therapeutics, Inc. She served as the Chief Executive Officer at Nile Therapeutics, Inc. Dr. Marbán’s scientific background is in cardiac physiology, an area in which She worked for two years as a postdoctoral fellow in Cardiology at the Johns Hopkins University, studied novel treatments for Myocardial Infarction (MI) in animal models. After a year on the faculty in the Department of Pediatrics at Johns Hopkins, Dr. Marbán joined the biotech start up company Excigen, Inc. as its Vice President for Business Development. In 2005, she was promoted to Vice President for Operations, in which she was responsible for raising capital from Medtronic Corporation through a Series A-2 Preferred Stock financing round. She serves as a Director of Capricor Therapeutics, Inc. since November 2013. She served as a Director of Nile Therapeutics, Inc. Dr. Marbán began her career in academic science, first at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. She advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure at Johns Hopkins University (“JHU”). Her tenure at JHU ran from 2000 to 2003. Dr. Marbán earned a Ph.D. from Case Western Reserve University in cardiac physiology.

CEO Compensation
  • Linda's compensation has increased whilst company is loss making.
  • Linda's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Capricor Therapeutics management team in years:

4.2
Average Tenure
55
Average Age
  • The tenure for the Capricor Therapeutics management team is about average.
Management Team

Frank Litvack

TITLE
Executive Chairman
COMPENSATION
$163K
AGE
62

Linda Marbán

TITLE
Co-Founder
COMPENSATION
$602K
AGE
55
TENURE
9.3 yrs

Karen Krasney

TITLE
Executive VP
COMPENSATION
$310K
AGE
65
TENURE
7.1 yrs

Deborah Ascheim

TITLE
Consultant
COMPENSATION
$348K
AGE
53
TENURE
0.4 yrs

Eduardo Marbán

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Anthony Bergmann

TITLE
CFO & Corporate Treasurer
AGE
32
TENURE
1.3 yrs

Catherine Kelleher

TITLE
Consultant
Board of Directors Tenure

Average tenure and age of the Capricor Therapeutics board of directors in years:

5.4
Average Tenure
62
Average Age
  • The tenure for the Capricor Therapeutics board of directors is about average.
Board of Directors

Frank Litvack

TITLE
Executive Chairman
COMPENSATION
$163K
AGE
62

Linda Marbán

TITLE
Co-Founder
COMPENSATION
$602K
AGE
55
TENURE
5.4 yrs

Eduardo Marbán

TITLE
Co-Founder & Chairman of Scientific Advisory Board

Duke Collier

TITLE
Director
COMPENSATION
$50K
AGE
71
TENURE
5.4 yrs

David Musket

TITLE
Director
COMPENSATION
$63K
AGE
60
TENURE
5.4 yrs

George Dunbar

TITLE
Director
COMPENSATION
$46K
AGE
71
TENURE
5.4 yrs

Louis Manzo

TITLE
Director
COMPENSATION
$42K
AGE
80
TENURE
5.4 yrs

Joshua Kazam

TITLE
Director
COMPENSATION
$29K
AGE
41
TENURE
13.7 yrs

Thomas Voit

TITLE
Member of Scientific Advisory Board

Ron Victor

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Capricor Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Capricor Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Investor Owns Most Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)?

A look at the shareholders of Capricor Therapeutics, Inc. … With a market capitalization of US$20m, Capricor Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Capricor Therapeutics

Simply Wall St -

Based On Its ROE, Is Capricor Therapeutics, Inc. (NASDAQ:CAPR) A High Quality Stock?

Capricor Therapeutics has a ROE of 5.4%, based on the last twelve months. … One way to conceptualize this, is that for each $1 of shareholders' equity it has, the company made $0.054 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

One Thing To Remember About The Capricor Therapeutics, Inc. (NASDAQ:CAPR) Share Price

The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks on the market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Reflect Performance?

Linda Marbán became the CEO of Capricor Therapeutics, Inc. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Linda Marbán's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Could Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Investor Composition Influence The Stock Price?

The big shareholder groups in Capricor Therapeutics, Inc. … With a market capitalization of US$16m, Capricor Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Capricor Therapeutics

Simply Wall St -

How Financially Strong Is Capricor Therapeutics, Inc. (NASDAQ:CAPR)?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … Debt funding can be cheaper than issuing new equity due to lower interest cost on debt

Simply Wall St -

How Good Is Capricor Therapeutics Inc (NASDAQ:CAPR), When It Comes To ROE?

Our data shows Capricor Therapeutics has a return on equity of 18% for the last year. … That means that for every $1 worth of shareholders' equity, it generated $0.18 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

A Spotlight On Capricor Therapeutics Inc's (NASDAQ:CAPR) Fundamentals

Attractive stocks have exceptional fundamentals. … In the case of Capricor Therapeutics Inc (NASDAQ:CAPR), there's … financially-robust

Simply Wall St -

Who Owns Capricor Therapeutics Inc (NASDAQ:CAPR)?

I am going to take a deep dive into Capricor Therapeutics Inc’s (NASDAQ:CAPR) most recent ownership structure, not a frequent subject of discussion among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Can Capricor Therapeutics Inc (NASDAQ:CAPR) Continue To Outperform Its Industry?

Capricor Therapeutics Inc (NASDAQ:CAPR) delivered an ROE of 23.03% over the past 12 months, which is an impressive feat relative to its industry average of 18.07% during the same period. … Sustainability can be gauged by a company’s financial leverage – the more debt it has, the higher ROE is pumped up in the short term, at the expense of long term interest payment burden. … See our latest analysis for Capricor Therapeutics

Simply Wall St -

Company Info

Description

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. Its development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Details
Name: Capricor Therapeutics, Inc.
CAPR
Exchange: NasdaqCM
Founded: 2005
$17,038,927
34,512,715
Website: http://www.capricor.com
Address: Capricor Therapeutics, Inc.
8840 Wilshire Boulevard,
2nd Floor,
Beverly Hills,
California, 90211,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CAPR New Common Stock Nasdaq Capital Market US USD 22. Nov 2013
BST 4LN1 New Common Stock Boerse-Stuttgart DE EUR 22. Nov 2013
LSE 0HTB New Common Stock London Stock Exchange GB EUR 22. Nov 2013
Number of employees
Current staff
Staff numbers
20
Capricor Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 00:09
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.